Press release
PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024
SEONGNAM, South Korea - PharmaResearch, a leading pharmaceutical/medical device research company, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to 10th in San Diego, California. The company will unveil research findings regarding its groundbreaking anticancer agent, PRD-101, through a poster session.
The presentations will cover diverse topics, including the efficacy demonstrated in various patient-derived xenograft (PDX) animal models and the results of in-depth characterization conducted by the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL).
Presentation Details
Poster Title: Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study Date and Time: Tuesday April 9, 1:30 AM - 5:00 PM PT
Session Category: Chemistry
Session Title: Drug Delivery
Session Location: Section 20
Poster Board Number: 3
Abstract number: 5735
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimization technology (DOTTM) in nano-particle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive license associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. The company is committed to advancing quickly into clinical trials based on promising safety and efficacy results obtained from preclinical studies.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOTTM PDRN and DOTTM PN. These active tissue regenerative substances are powered by DOTTM, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, Califrornia, US.
PharmaResearch's participation in the AACR Annual Meeting underscores its dedication to pioneering advancements in cancer research and treatment, ultimately aiming to improve patient outcomes and quality of life.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en
Media Contact
Company Name: PharmaResearch USA.
Contact Person: Sangjin Choi
Email: Send Email [http://www.universalpressrelease.com/?pr=pharmaresearch-to-present-the-research-on-its-nano-anticancer-drug-prd101-at-the-aacr-annual-meeting-2024]
Country: United States
Website: http://pharmaresearch.co.kr/en/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024 here
News-ID: 3444393 • Views: …
More Releases from Getnews
Manhattan Elderly Care Tackles Top Senior Worries Through Guided Active Aging fr …
Image: https://www.globalnewslines.com/uploads/2025/09/1757439777.jpg
A compassionate intentional approach helps NYC seniors age at home safely while enjoying autumn activities and combating isolation during Active Aging Week
NEW YORK, NY - September 15, 2025 - A recently published study from the New York City Department for the Aging reveals a pressing urban health crisis: over 25% of the city's seniors live alone, a primary driver of an isolation epidemic that the National Institute on Aging…
Inspire Ambitions Unveils New Report Showing Graduate Expectation Gap in the UAE …
Inspire Ambitions launches "The 2025 Graduate Expectation Gap Report," highlighting disconnects between student career expectations and workplace realities.
Image: https://www.globalnewslines.com/uploads/2025/09/6f6df43eab6fb7f22996fcc669a39629.jpg
A new report released today by Inspire Ambitions [https://inspireambitions.com/], The 2025 Graduate Expectation Gap Report [https://inspireambitions.com/product/from-campus-to-career/], reveals that a significant majority of recent graduates in the UAE feel unprepared for the realities of today's workplace. The findings shed light on a widening divide between university preparation and the skills needed to succeed…
Future Electronics and Infineon to Host Free Webinar on Next-Generation Smart HM …
Image: https://www.globalnewslines.com/uploads/2025/09/1757697276.jpg
Future Electronics & Infineon's free webinar on Sept 25 to explore how PSOC Trademark Edge powers next-gen smart HMIs with AI, voice & gesture control.
Montreal, Canada - September 12, 2025 - Future Electronics, a leading global distributor of electronic components, is pleased to announce an upcoming free webinar hosted in collaboration with Infineon Technologies: Unlock Innovation with PSOC Trademark Edge for Next-Gen Smart HMIs.
The live session will take place…
RoadMap Advisors Enhances Sell-Side M&A Services for Middle Market Business Owne …
Image: https://www.globalnewslines.com/uploads/2025/09/1757662626.jpg
RoadMap Advisors, a Virginia-based consulting firm, has refined its sell-side M&A service offerings to provide greater process efficiency, buyer alignment, and transaction readiness for business owners seeking full or partial exits.
Vienna, VA - September 12, 2025 - RoadMap Advisors, a leading consulting firm in Tysons, VA [https://www.roadmapadvisors.com/], has announced the refinement of its sell-side mergers and acquisitions (M&A) services [https://www.roadmapadvisors.com/mergers-acquisitions/sell-side/], incorporating a structured, advisor-led process designed to help business…
More Releases for PharmaResearch
Polynucleotides Injectable Overview and Leading Players: Euroresearch S, NeoGene …
The Polynucleotides Injectable market is rapidly gaining traction as a pivotal segment within the aesthetic and medical sectors. Polynucleotides, naturally occurring polymers of nucleotides, have emerged as a revolutionary ingredient in injectables, primarily due to their ability to stimulate tissue regeneration and enhance skin hydration. The relevance of this market is underscored by its applications in various therapeutic and aesthetic procedures, including skin rejuvenation, wrinkle reduction, and overall facial volumization.
𝐘𝐨𝐮…
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
Over 600 Medical Professionals from 25 Countries Participate, Launch of IRC Committee for Rejuran Global Research Team
Image: https://www.getnews.info/uploads/184db9fd8e5f5bcffadcfd0b82962264.png
Seongnam, South Korea - PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch Global Symposium (PGS) at the Lakai Sandpine Resort on October 28-29, 2024. This year's event attracted approximately 600 aesthetic and medical professionals from 25 countries across Asia, the Americas, Europe, and the…
PharmaResearch Accelerates Global Market Expansion with Investment from Global P …
Accelerating Overseas Expansion and Market Strengthening through CVC Partnership, M&As, and R&D Investments
Image: https://www.getnews.info/uploads/37d3d1ec3a03e85dac6376b2c2e3bb4e.jpg
September 13th, 2024 - PharmaResearch (co-CEOs: Kang Ki Seock, Kim Thinkyou), a leader in aesthetic injectables and regenerative medicines renowned for its flagship skin booster product "Rejuran", announced a significant milestone in its global market expansion efforts, securing KRW 200 billion investment from Europe-based global private equity firm CVC through the issuance of redeemable convertible preferred shares…
PharmaResearch Announces 'Open Innovation Day' Running Until September 30 to Fos …
Anticipating Collaborations with Leading Companies in Aesthetic Medical Devices, Pharmaceuticals and Biotechnology: Application Period August 15 - September 30
Image: https://www.getnews.info/uploads/3276751a42ffba8429fb959e81d25795.jpg
PharmaResearch, a company specializing in regenerative medicine (CEO Kim Thinkyou, Kang Ki-seock), announced that it will host the 'Open Innovation Day'. This initiative aims to foster collaborations in innovative technologies across the aesthetic medical device, pharmaceuticals, biotechnology sectors, both domestically and internationally.
PharmaResearch is seeking partnerships in several key areas, including -…
PharmaResearch Hosts Launch Symposium for REJURAN Registered HB Plus in Singapor …
Sharing information on DOT Trademark patented technology, distinctive efficacy, and safety
Image: https://www.getnews.info/uploads/a9dbc52352e6614785a6dbafd0148817.png
PharmaResearch (CEOs Kang Ki-seok and Kim Thinkyou), a company specializing in regenerative medicine, announced earlier this month that it held a launch symposium for REJURAN Registered HB Plus at Four Seasons Hotel in Singapore.
The symposium aimed to share the technological advancements and clinical experiences of REJURAN Registered HB Plus with local aesthetic experts and medical professionals.
Dr. Michael J. Kim,…
PharmaResearch Presents 'REJURAN Registered ' as a New Solution for Flushing
Effective Use of PN for Flushing... Published in an SCIE-Level Journal
Image: https://www.getnews.info/uploads/52b03d248c2ca7ae3fdd1f69ef67ba5c.png
Flushing refers to the temporary or persistent redness of the skin on the face and neck. It occurs due to vasodilation and is known to arise from various causes, such as hormonal changes, sudden temperature fluctuations, inflammatory skin diseases, and prolonged laser treatments.
While laser and hormone therapies are common treatments for flushing, PharmaResearch(CEO Kim Thinkyou, Kang Ki-seok) has recently…
